SCHEMBL24617475

SCHEMBL24617475

CNC(=O)c1cccc([C@@H](C)n2cnc3cc(-c4conc4C)ccc3c2=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.38
TSHR P16473 1/20 0.38
GRK2 P25098 2/20 0.37
TAF1 P21675 1/20 0.34
EGFR P00533 2/20 0.34
ROCK2 O75116 2/20 0.34
ESR1 P03372 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
NR3C2 P08235 1/20 0.33
AR P10275 1/20 0.33
ESR2 Q92731 1/20 0.33
USP5 P45974 1/20 0.33
RAF1 P04049 3/20 0.33
BRAF P15056 3/20 0.33
CDK9 P50750 1/20 0.32
SLC2A1 P11166 1/20 0.32
BMPR1B O00238 1/20 0.32
ACVRL1 P37023 1/20 0.32
ACVR1 Q04771 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24617003 1.00 GCK (0.38) GCKTSHRGRK2TAF1EGFR
SCHEMBL29778540 0.94 TSHR (0.36) GCKTSHRGRK2EGFRESR1
SCHEMBL29778513 0.88 TSHR (0.34) TSHRGRK2ESR1NR3C1PGR
SCHEMBL24617525 0.88 TSHR (0.34) TSHRGRK2ESR1NR3C1PGR
SCHEMBL24617480 0.88 TSHR (0.38) TSHRGRK2TAF1EGFRESR1
SCHEMBL29779119 0.87 GRK2 (0.37) GCKTSHRGRK2TAF1ROCK2
SCHEMBL24617564 0.87 GRK2 (0.37) GCKTSHRGRK2TAF1ROCK2
SCHEMBL24616904 0.87 TAF1 (0.36) TAF1EGFRROCK2ESR1NR3C1
SCHEMBL24617523 0.84 TNKS2 (0.43)
SCHEMBL24617495 0.84 ROCK2 (0.38) ROCK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 GCK 2994/4885TSHR 4258/4885GRK2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.